BridgeBio Pharma, Inc.
BBIO
$61.37
-$0.61-0.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.17% | -5.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.17% | -5.20% | |||
| Cost of Revenue | 79.66% | 38.42% | |||
| Gross Profit | 6.76% | -6.21% | |||
| SG&A Expenses | 6.56% | 21.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.34% | 10.71% | |||
| Operating Income | -2.16% | -28.58% | |||
| Income Before Tax | -2.66% | -7.10% | |||
| Income Tax Expenses | -173.57% | -- | |||
| Earnings from Continuing Operations | -0.64% | -8.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 18.27% | -15.14% | |||
| Net Income | -0.46% | -8.65% | |||
| EBIT | -2.16% | -28.58% | |||
| EBITDA | -2.12% | -28.91% | |||
| EPS Basic | 0.24% | -8.44% | |||
| Normalized Basic EPS | 2.79% | -22.97% | |||
| EPS Diluted | 0.24% | -8.44% | |||
| Normalized Diluted EPS | 2.79% | -22.97% | |||
| Average Basic Shares Outstanding | 0.70% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.70% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||